BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC

Not yet recruiting

• Conditions: Prostate Cancer Metastatic

• Registration Number: NCT05530395
• Lead Sponsor: Ignacio Puche Sanz

Brief Summary

Despite large amounts of basic-science data supporting a role for androgens in PCa pathogenesis, there are conflicting clinical data on the role of endogenous testosterone in human de novo PCa pathogenesis. The investigators hypothesize that lower baseline serum testosterone is significantly associated with worse clinical outcomes in mHSPC patients undergoing continuous medical castration

Detailed Description

Biological rationale:

The 'androgen hypothesis' asserts that prostate cancer (PCa) development and progression is driven by androgens. There is significant evidence that androgens promote prostate cancer in experimental models. However, there is no clear evidence that elevations in endogenous testosterone levels promote the development of prostate cancer in humans. Indeed, despite large amounts of basic-science data supporting a role for androgens in PCa pathogenesis, there are conflicting clinical data on the role of endogenous testosterone in human PCa pathogenesis de novo. In reviewing the literature involving PCa development in PCa naive patients, there are studies implicating elevated testosterone, studies implicating lower testosterone, and studies with no association of testosterone and PCa risk.

A recent review in 2015 delved into the controversial role of androgens and prostate cancer and explains the different theories about the ambiguous action of testosterone on the prostate. In 2012, a research proposed the nonlinear U-shaped behaviour or time dependency theory, which postulates that the endocrine biology of the prostate tissue depends on exposure time at a given androgen concentration, which "relies on the fluctuation of the levels of circulating sex steroids during the lifespan of the individual". Another model is the saturation model based on the observations that prostate tissue is extremely sensitive to changes in serum testosterone at low concentrations. This model suggests that there is a nonprotective effect of low testosterone against PCa but tissue becomes indifferent to changes when increasing androgen concentration reach a limit (saturation point), beyond which no further androgen-driven changes are observed. Anyway, the lack of a satisfying model to explain the relationship between androgens and PCa is simply the consequence of insufficient knowledge of the real intrinsic physiopathology of this disease.

Clinical rationale:

Approximately 15% of mHSPC patients primarily fail to respond to ADT. A recent consensus statement on circulating biomarkers for advanced prostate cancer highlighted the urgent need for prospective trials to clinically qualify circulating biomarkers, the greatest need being metastatic PCa. On the other hand, a very recent paper analysed baseline testosterone in hormone-naïve advanced PCa patients undergoing continuous medical castration and selected from 2 large Phase III RCTs. It demonstrated that lower baseline serum testosterone was significantly associated with worse survival end-points and warrants further prospective research in this scenario.

In this era of complex and expensive next-generation markers, this simple, cheap, and well-known biomarker may still have something to say in PCa.

Study Timeline

• Status Verified: 2022-09
• Study First Submitted: 2022-09-02
• Study First Submitted QC: 2022-09-02
• Study First Posted: 2022-09-07
• Last Update Submitted: 2022-09-09
• Last Update Posted: 2022-09-14
• Study Start: 2023-01-01
• Primary Completion: 2025-01-01
• Study Completion: 2026-01-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Male
• Target Recruitment: 300

Inclusion Criteria

• Metastatic hormone sensitive prostate cancer (mHSPC) patients diagnosed by any imaging test (at least CT and bone scan) including:

  • Any newly diagnosed mHSPC with no prior treatments.
  • Primarily treated PCa that have progressed to mHSPC with no prior ADT in the last 2 years.
  • Patients receiving ADT + EBRT as primary treatment will also be included.

• Patients who agree to be followed prospectively according to routine clinical practice in the context of this study.

Exclusion Criteria

• Any prior androgen deprivation therapy (ADT) scheme 2 years before recruitment. - Any prior testosterone replacement therapy scheme 2 years before recruitment.
• Previous intermittent ADT schemes.
• Prior testicular excision surgery.
• Absence or testicular atrophy from any cause.
• Whenever further prospective clinical follow-up is not possible or patient do not accept follow-up in the context of this study.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Early treatment failure	1 year	Proportion of patients with PSA progression or death from PCa within 12 months after initiation of treatment.
PSA response	6 months	Lowest PSA (nadir) reached after initiation of treatment

Secondary Outcome Measures

Name	Time	Method
Radiologic progression-free survival (rPFS)	1 year	Assessed by PCWG3 progression criteria on nodal, visceral and bone disease.
Time to CRPC	1 year	Time (months) from treatment initiation to the development of a CRPC status.
Testosterone response.	6 months	%percent of decrease in testosterone levels at the moment of PSA nadir.
Biochemical progression-free survival (bPFS)	1 year	PSA progression: 2 consecutive increase at least 50% or 5 ng/mL or more above PSA nadir on 2 consecutive measurements at least 2 weeks apart.

Trial Locations

Locations (3)

Hospital Universitario Reina Sofía; 🇪🇸 Córdoba, Andalucía, Spain

Hospital Universitario Virgen de las Nieves; 🇪🇸 Granada, Andalucía, Spain

Hospital Universitario Virgen del Rocio; 🇪🇸 Seville, Spain